M O 5
Pill imprint M O 5 has been identified as Oxybutynin chloride extended release 5 mg.
Oxybutynin is used in the treatment of overactive bladder; urinary incontinence; dysuria; hyperhidrosis; prostatitis and belongs to the drug class urinary antispasmodics. There is no proven risk in humans during pregnancy.
Oxybutynin 5 mg is not subject to the Controlled Substances Act.
See also related documents.
Oxybutynin chloride extended release Images
- Imprint:
-
M O 5
- Strength:
- 5 mg
- Color:
- Green
- Size:
- 8.00 mm
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Urinary antispasmodics
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- 00378-6605
| NDC Code | Manufacturer / Repackager |
|---|---|
| 51079-0722 | UDL Laboratories Inc |
| 16590-0321 | Stat RX USA LLC (repackager) |
Note: Inactive ingredients may vary.
More Oxybutynin Chloride Extended Release resources
- Oxybutynin
- Oxybutynin (Wolters Kluwer)
- Oxybutynin Extended-Release Tablets (Wolters Kluwer)
- Oxybutynin Gel (Wolters Kluwer)
- Oxybutynin Syrup (Wolters Kluwer)
- Oxybutynin System (Wolters Kluwer)
- oxybutynin (Cerner Multum)
- oxybutynin topical (Cerner Multum)
- oxybutynin transdermal (Cerner Multum)
- oxybutynin (Micromedex) - Includes Dosage Information
- oxybutynin Transdermal (Micromedex) - Includes Dosage Information
- Oxybutynin Chloride (AHFS DI)
- Oxybutynin (FDA)
- Oxybutynin Chloride (FDA)
- Oxybutynin Oral Solution (FDA)
- Oxybutynin Syrup (FDA)
- Oxybutynin Chloride (Wolters Kluwer)


